Premium
Overview of the profile of tafluprost
Author(s) -
UUSITALO HMT
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2008.6274.x
Subject(s) - latanoprost , bimatoprost , travoprost , adverse effect , pharmacology , medicine , prostaglandin analogue , ocular hypertension , glaucoma , ophthalmology
Purpose Tafluprost (Taflotan®) is a new potent PGF2_ analogue for the treatment of glaucoma. Tafluprost is the first prostaglandin available as a preservative free formulation. This presentation summarizes the pre‐clinical and clinical profile of tafluprost. Results Tafluprost is a potent and selective FP receptor agonist. It lowers IOP by mainly increasing the uveoscleral outflow. Tafluprost had potent IOP lowering effect in normotensive and ocular hypertensive monkeys, unsurpassed by latanoprost. In healthy volunteers tafluprost was well tolerated, safe and effective in IOP lowering. Based on dose response data 15 micrograms/ml was chosen as the final concentration. This concentration had a comparable IOP lowering effect to latanoprost in P‐II studies. Effective IOP lowering was confirmed in pivotal clinical studies. All adverse effects reported were well known for the prostaglandin analogues. The most frequently reported adverse event was hyperaemia. It was reported in 13% of patients. A preservative free form of tafluprost showed equal efficacy and pharmacokinetics to the preserved form. Preservative free tafluprost has low or no pro‐apoptotic, pronecrotic or pro‐oxidative effects in vitro compared to preservative‐containing prostaglandin formulations latanoprost, travoprost and bimatoprost. Conclusion Tafluprost (Taflotan®) is a new effective, well tolerated and safe IOP reducing agent. Importantly Tafluprost is the first prostaglandin analogue commercially available as preservative‐free formulation. There is a growing body of evidence that this has a clinical relevance in the treatment of chronic diseases like glaucoma and especially in patients with dry/sensitive eyes.